Clinical Trials
3 trialsNCT04948333 2026-03-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Phase 3 Completed
NCT04666259 2025-10-16
AIM4CML
Novartis
Phase 3 Completed
NCT03106779 2025-04-08
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Novartis
Phase 3 Completed